



10/502031

GB03/342



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road

Newport
South Wales

NP10 8QQ

REC'D 28 FEB 2003

WIPO

PCT

PRIORITY DOCUMENT


SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated

19 February 2003

The
Patent
Office



STAMPED 5/01/2004 1 003312
27 JAN 02 0671324-1 003312
P01/7700 0.00-0201896.8

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

0201896.8

1. Your reference **GBP8528**

2. Patent application number
(The Patent Office will fill in this part)

3 Full name, address and postcode of the or of each applicant (underline all surnames)

ICE Biologics Limited,
4 Gildridge Road
Eastbourne
East Sussex BN21 4RL
United Kingdom

28 JAN 2002

Patents ADP number (if you know it)

8179871001

If the applicant is a corporate body, give the country/state of its incorporation

4. Title of the invention **TREATMENT**

5. Name of your agent (if you have one)
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

Marks & Clerk
57 - 60 Lincolns Inn Fields
London WC2A 3LS

Patents ADP number (if you know it)

18001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application No
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

3. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

Yes

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d))

Patents Form 1/77

Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form

0

Description

2

Claim(s)

Abstract

Drawing(s)

10. If you are also filing any of the following,
state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right
to grant of a patent (Patents Form 7/77)

Request for preliminary examination
and search (Patents Form 9/77)

Request for substantive examination
(Patents Form 10/77)

Any other documents
(please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature

Marks & Clerk

Date: 28 January 2002

12. Name and daytime telephone number of
person to contact in the United Kingdom

GB Patent Filings
0207 400 3000

Treatment

The present invention relates to the treatment of diseases.

Our PCT application GB 01/03292 as well our GB patent applications GB 116151.2 and GB 128638.4 relate to therapeutic agents which find application in the treatment of HIV. They describe a serum which has been shown to have anti-HLA and anti-FAS activities.

The present invention provides for the use of such therapeutic agents in the treatment of other diseases. The PCT/GB 01/03292, GB 116151.2 and GB 128638.4 are incorporated herein in full by reference, particularly for details of the preparation of the therapeutic agents.

The main use of the present invention is for the sera containing anti-HLA as a treatment for diseases expressing inappropriate HLA. These include multiple sclerosis, rheumatoid arthritis, diabetes mellitus, primary biliary cirrhosis, cirrhosis autoimmune and viral b and c autoimmune conditions involving heart, lung, skin, gastrointestinal tract, kidney, brain, CNS.

The presence of anti-FAS makes the sera particularly suitable for diseases associated with chronically activated cells which may be secreting damaging messengers such as cytokines and chemokines. These include multiple sclerosis, all forms of chronic inflammatory conditions of the nervous system as well as of chronic infections such as viral, bacterial and tropical cancers associated with chronic inflammatory lesions, in particular those of the lung, pancreas, liver, bowel, lymph nodes, skin especially squamous cell and basal cell cancers may also benefit primary and secondary tumours of the brain and spinal cord.

The observed improvements in nervous function in those people with traumatic damaged nerves suggests a neuronal growth factor property and hence may be used for trauma, post infectious damage eg guillian-barre,

malignancy damage etc, neuropathies associated with diabetes, alcoholism, poisoning with metals or other toxins etc.

The observed benefits on the hair and skin tone and color suggest other unique properties which cannot be explained by the above observations re antibodies etc to date ie anti-ageing, reports of reduced secondary cancer activity with this sera suggest direct anti cancer activity this may be related to FAS activity but may also be due to other as yet unidentified agents.

Thus, the present invention relates to further medical indications for the therapeutic agents of our incorporated applications. It provides methods of treatment, as well as methods of preparing medicaments for use in the treatments. Pharmaceutical compositions are provided.